SLC3A2 and breast carcinoma: After showing that SLC7A5/SLC3A2 co-expression was associated with a worse outcome in patients with ER+ breast cancer, we next asked whether SLC7A5/SLC3A2 co-expression correlates with endocrine sensitivity.